Last reviewed · How we verify
Glycopyrrolate
Glycopyrrolate is a Small molecule drug developed by Yonsei University. It is currently FDA-approved for Chronic obstructive lung disease, Excessive salivation, General anesthesia. Also known as: Glycopyrrolate, Parasympathetic blockade, Robinul, Foster+GLyco 25.
Glycopyrrolate is a small molecule medication that belongs to the muscarinic anticholinergic group. It can be administered via various routes, including inhalation, and is used to treat conditions such as COPD, as indicated by clinical trials.
At a glance
| Generic name | Glycopyrrolate |
|---|---|
| Also known as | Glycopyrrolate, Parasympathetic blockade, Robinul, Foster+GLyco 25, Foster+GLyco 50 |
| Sponsor | Yonsei University |
| Target | Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Chronic obstructive lung disease
- Excessive salivation
- General anesthesia
- Hyperhidrosis of axilla
- Peptic ulcer
- Vagal Reflex Bradycardia
Common side effects
- Dry mouth
- Constipation
- Blurred vision
- Urinary retention
- Vomiting
- Tachycardia
- Drowsiness
- Decreased sweating
- Flushing
- Nausea
- Headache
- Dizziness
Serious adverse events
- Anaphylaxis
- Respiratory depression
- Acute glaucoma
- Mechanical intestinal obstruction
- Heat prostration
- Chest pain
- Hypertension
- Cycloplegia
- Increased ocular tension
- Throat irritation
Key clinical trials
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture (PHASE2)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
- Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
- A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 10940110 | 2029-02-26 | Formulation |
| 10744277 | 2036-12-07 | Formulation |
| 10376661 | 2035-09-14 | Formulation |
| 9789270 | 2030-10-30 | Formulation |
| 11278683 | 2026-08-16 | Formulation |
| 9604018 | 2033-05-16 | Formulation |
| 8479730 | 2028-10-11 | Formulation |
| 9168556 | 2032-09-01 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glycopyrrolate CI brief — competitive landscape report
- Glycopyrrolate updates RSS · CI watch RSS
- Yonsei University portfolio CI
Frequently asked questions about Glycopyrrolate
What is Glycopyrrolate?
Glycopyrrolate is a Small molecule drug developed by Yonsei University, indicated for Chronic obstructive lung disease, Excessive salivation, General anesthesia.
What is Glycopyrrolate used for?
Glycopyrrolate is indicated for Chronic obstructive lung disease, Excessive salivation, General anesthesia, Hyperhidrosis of axilla, Peptic ulcer.
Who makes Glycopyrrolate?
Glycopyrrolate is developed and marketed by Yonsei University (see full Yonsei University pipeline at /company/yonsei-university).
Is Glycopyrrolate also known as anything else?
Glycopyrrolate is also known as Glycopyrrolate, Parasympathetic blockade, Robinul, Foster+GLyco 25, Foster+GLyco 50.
What development phase is Glycopyrrolate in?
Glycopyrrolate is FDA-approved (marketed).
What are the side effects of Glycopyrrolate?
Common side effects of Glycopyrrolate include Dry mouth, Constipation, Blurred vision, Urinary retention, Vomiting, Tachycardia. Serious adverse events: Anaphylaxis, Respiratory depression, Acute glaucoma, Mechanical intestinal obstruction.
What does Glycopyrrolate target?
Glycopyrrolate targets Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3.
Related
- Target: All drugs targeting Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
- Manufacturer: Yonsei University — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Chronic obstructive lung disease
- Indication: Drugs for Excessive salivation
- Indication: Drugs for General anesthesia
- Also known as: Glycopyrrolate, Parasympathetic blockade, Robinul, Foster+GLyco 25, Foster+GLyco 50
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing